Example ImageÃÀ¸ß÷

EN
EN
  • ÓªÒµ×Éѯ

    Öйú£º

    Email: marketing@medicilon.com.cn

    ÓªÒµ×ÉѯרÏߣº400-780-8018

    £¨½öÏÞЧÀÍ×Éѯ£¬ £¬£¬£¬£¬£¬ÆäËûÊÂÒËÇ벦´ò´¨É³×ܲ¿µç»°£©

    ´¨É³×ܲ¿µç»°: +86 (21) 5859-1500

    ÍâÑó£º

    +1(781)535-1428(U.S.)

    0044 7790 816 954 (Europe)

    Email:marketing@medicilon.com

ÔÚÏßÁôÑÔ¡Á
µã»÷Çл»
News information
ÐÂÎÅ×ÊѶ

APA 2023 | ÃÀ¸ß÷º£±¨Õ¹³ö£¬ £¬£¬£¬£¬£¬·ÖÏíADMET¡¢PKºÍÉúÎïÆÊÎö¶ÔÒ©ÎïÑз¢µÄÍÆÐж¯ÓÃ

2023-09-25
|
»á¼ûÁ¿£º

Applied Pharmaceutical Analysis, APA 2023.jpg

2023ÄêÓ¦ÓÃÒ©ÎïÆÊÎö×êÑлᣨApplied Pharmaceutical Analysis, APA 2023£©½«ÓÚ9ÔÂ26ÈÕÖÁ28ÈÕÔÚ²¨Ê¿¶Ù¡¤Ä¬¿ËÑо¿ÊµÑéÊÒ¾ÙÐС£¡£¡£¡£¡£

Ó¦ÓÃÒ©ÎïÆÊÎö (APA) Óɲ¨Ê¿¶ÙЭ»á£¨501(c)3 ·ÇÓªÀû×éÖ¯£©ÓÚ 2004 Ä꽨É裬 £¬£¬£¬£¬£¬ÊÇÒ»¸öÒÔÐÐÒµÎªÖØµã¡¢»¥¶¯ÐÔ¼«Ç¿µÄÂÛ̳£¬ £¬£¬£¬£¬£¬ÌÖÂÛÒ©Îï·¢Ã÷¡¢ÉúÎïת»¯ºÍ¹æ·¶ÉúÎïÆÊÎö¡£¡£¡£¡£¡£Ã¿Äê9ÔÂÓɲî±ðµÄ¿ÆÑ§´ø¶¯ÈË×éÖ¯¿ªÕ¹¾Û»á£¬ £¬£¬£¬£¬£¬Î§ÈƵ±ËÞÊÀÎïÆÊÎöºÍÒ©ÎïÑз¢ÖÐÉúÎïת»¯µÄÇ°ÑØ¼¼ÊõºÍÓ¦ÓÃÏ£Íû½á¹¹»°Ì⣬ £¬£¬£¬£¬£¬ÏòËùÓиÐÐËȤµÄ¿ÆÑ§¼Ò¿ª·Å¡£¡£¡£¡£¡£

APA 2023½«Î§ÈÆÒÔÏÂÆ«ÏòÕö¿ª£ºÉúÎïÆÊÎö¼°Æäî¿Ïµ¡¢Ì½Ë÷ÉúÎïÆÊÎöм¼Êõ¡¢ADMEµÈ¡£¡£¡£¡£¡£

ÃÀ¸ß÷ÍŶӽ«¼ÓÈë±¾´Î¾Û»á£¬ £¬£¬£¬£¬£¬²¢´øÀ´¡°The Boost of ADMET, PK and Bioanalysis for Drug Discovery and Development¡±£¨ADMET¡¢PKºÍÉúÎïÆÊÎö¶ÔÒ©ÎïÑз¢µÄÍÆÐж¯Ó㩾«²Êº£±¨£¬ £¬£¬£¬£¬£¬ÏòÌýÖÚ·ÖÏíÖÖÖÖ×îа¸Àý£¬ £¬£¬£¬£¬£¬ÆÚ´ýÓëÄú¾ÍÐÂÒ©Ñз¢ÐèÇó½»Á÷Ïàͬ¡£¡£¡£¡£¡£

¾«²Êº£±¨ÕùÏÈ¿´£¡É¨Ãè¶þάÂë¼´¿ÉÏÂÔØ

¾«²Êº£±¨ÕùÏÈ¿´£¡É¨Ãè¶þάÂë¼´¿ÉÏÂÔØ.jpg

ÈÕÆÚ | 2023Äê9ÔÂ26-28ÈÕ

ËùÔÚ | Ĭ¿ËÑо¿ÊµÑéÊÒ£¬ £¬£¬£¬£¬£¬²¨Ê¿¶Ù£¬ £¬£¬£¬£¬£¬ÃÀ¹ú

ÃÀ¸ß÷չλ | #1

Òé³ÌËÙµÝ

Ò©´ú¶¯Á¦Ñ§¹á´®ÓÚÐÂÒ©Ñз¢µÄʼÖÕ£¬ £¬£¬£¬£¬£¬Ã¿¸ö½×¶Î¶¼Óвî±ðµÄʹÃüºÍÓë֮ƥÅäµÄÑо¿ÄÚÈÝ¡£¡£¡£¡£¡£

¾ÝÔ¤¼Æ£¬ £¬£¬£¬£¬£¬½ü50£¥µÄºòѡҩÎïÒòÁÆÐ§²»¼Ñ¶øÊ§°Ü£¬ £¬£¬£¬£¬£¬ÒÑÍù40£¥µÄºòѡҩÎïÒò¶¾ÐÔ¶øÊ§°Ü£¬ £¬£¬£¬£¬£¬ADMEÑо¿¿É¼«ºéÁ÷ƽӰÏìÁÙ´²×îÖÕÀÖ³ÉÓë·ñ£¬ £¬£¬£¬£¬£¬ÔçÆÚÆÀ¹ÀADMEÌØÕ÷¹ØÓÚÓÅ»¯Ò©Îï·¢Ã÷ºÍ¿ª·¢Àú³Ì¾ßÓÐÇÐʵ¼ÛÖµ¡£¡£¡£¡£¡£³ýÁ˹ŰåµÄС·Ö×Ӻʹó·Ö×ÓÒ©ÎïÍ⣬ £¬£¬£¬£¬£¬ÏÖÔÚ¶ÔëÄÀàÒ©Îï¡¢¹ÑºËÜÕËáºÍADCÒ©ÎïµÈÐÂģʽµÄͶÈëÒ²´ó·ùÔöÌí£¬ £¬£¬£¬£¬£¬ÉúÎïÆÊÎöºÍʵÑ鹤¾ßÐèÒª½øÒ»²½Á¢Ò죬 £¬£¬£¬£¬£¬ÒÔÖ§³ÖÆäADMEÌØÕ÷Ñо¿¡£¡£¡£¡£¡£

±¾´Î¾Û»á°²ÅÅÁËÈý³¡Ö÷ÌⶨÏò×êÑУºî¿Ïµ¡¢¼¼ÊõºÍÓ¦Óᣡ£¡£¡£¡£ÃÀ¸ß÷¾«Ñ¡Á˾ۻáÒé³Ì£¬ £¬£¬£¬£¬£¬¹©Äú²Î¿¼¡£¡£¡£¡£¡£

Regulated Bioanalysis
ÉúÎïÆÊÎöî¿Ïµ×êÑÐ»á £¨9ÔÂ26ÈÕ£¬ £¬£¬£¬£¬£¬Öܶþ£©

Session I: Assessing the Current Landscape of FDA Regulations
£¨FDA¹æÔòµÄÏÖ×´ÆÀ¹À£©

Session II: Advances in Sampling Strategies: A dialogue with Joleen White & Lori Payne
£¨¶Ô»°×¨¼Ò£ºÈ¡Ñù²ßÂÔµÄÏ£Íû£©

Session III: Emerging Modalities & New Technologies
£¨ÐÂÐËģʽÓëм¼Êõ

Session IV: Immunogenicity Applications for Various Drug Modalities
£¨²î±ðÁÆ·¨ÏÂÃâÒßÔ­ÐÔÓ¦Óã©

Session V: Rapid Fire Poster Presentations
£¨º£±¨Õ¹Ê¾£©

Discovery Bioanalysis and New Technologies
·¢Ã÷ÉúÎïÆÊÎöºÍм¼Êõ×êÑлᣨ9ÔÂ27ÈÕ£¬ £¬£¬£¬£¬£¬ÖÜÈý£©

Session I: Leveraging Biomarkers & Integrating Multi-Omics for Biomarker Discovery
£¨Ê¹ÓÃÉúÎï±ê¼ÇÎïºÍÕûºÏ¶àÖ¸±ê·¢Ã÷ÉúÎï±ê¼ÇÎ

Session II: Applications of Precision Medicine in Drug Discovery Research
£¨¾«×¼Ò½Ñ§ÔÚÒ©Îï·¢Ã÷Ñо¿ÖеÄÓ¦Óã©

Session III: Advancing DMPK/Bioanalysis of PROTAC's
£¨ÍƽøPROTACµÄDMPK/ÉúÎïÆÊÎö£©

Session IV: Latest Advances in LC-MS
£¨LC-MS µÄ×îÐÂÏ£Íû£©

Mechanistic ADME Workshop
Ò©´ú¶¯Á¦Ñ§Ä£×Ó×êÑлᣨ9ÔÂ28ÈÕ£¬ £¬£¬£¬£¬£¬ÖÜËÄ£©

Session I: ADME of Select Modalities
£¨ADMEÄ£×ÓÑ¡Ôñ£©

Session II: Why is My Human ADMET Profile Not as Expected?
£¨ÎªÊ²Ã´ADMETÑо¿Ð§¹û²»ÈçÔ¤ÆÚ£¿£¿£¿£¿£¿£©

Session III: Applying Cutting-edge ADME Technologies
£¨ADMEÇ°ÑØ¼¼ÊõÓ¦Óã©

Session IV: Exploring Unconventional Biotransformation Pathways
£¨Ì½Ë÷·ÇͨÀýÉúÎïת»¯Í¾¾¶£©

¹ØÓÚÃÀ¸ß÷ADMETºÍPKЧÀÍ

ÃÀ¸ß÷ÔÚÌåÍâADME¡¢ÌåÄÚÒ©´ú¶¯Á¦Ñ§ºÍÉúÎïÆÊÎöЧÀÍÁìÓòΪ¿Í»§ÌṩÆÕ±éµÄ¸ßÖÊÁ¿Ð§ÀÍ£¬ £¬£¬£¬£¬£¬Ð§À͹æÄ£´ÓС·Ö×Óµ½´ó·Ö×Ó£¬ £¬£¬£¬£¬£¬ÈçÂѰ×ÖʺͿ¹Ìå¡£¡£¡£¡£¡£ÎÒÃÇÌṩЧÀ͵͝ÎïÖÖÀà°üÀ¨·ÇÈËÁ鳤ÀදÎȮ¡¢Ð¡Êó¡¢´óÊó¡¢ÍõÈ¡£¡£¡£¡£¡£

ÃÀ¸ß÷ÌåÍâADMEЧÀÍ

ÃÀ¸ß÷ÌåÄÚÒ©´ú¶¯Á¦Ñ§Ð§ÀÍ

ÃÀ¸ß÷ÉúÎïÆÊÎöЧÀÍ

Ïà¹ØÐÂÎÅ
¡¾ÔÆ¿ÎÌá¿ÈýλһÌå½â˵˫¿¹µÄÉúÎïÆÊÎö
2020-09-03
Ëæ×ÅË«¿¹¼¼ÊõµÄÉú³¤£¬ £¬£¬£¬£¬£¬Ë«¿¹ÏÖÔÚ·ºÆð³öÓÅÒìµÄÉú³¤Ô¶¾°£¬ £¬£¬£¬£¬£¬¸÷ÖÁ¹«Ë¾Ôڽṹ˫¿¹²úÆ·Ñз¢µÄͬʱ£¬ £¬£¬£¬£¬£¬Ò²Ðè¹Ø×¢ÔÚË«¿¹µÄ¼ì²âºÍÆÊÎöÖÐÓÐÐí¶àÐèÒªÕë¶ÔÕâÖÖ¼¼Êõ¶ø¼ÓÒÔ×¢ÖØºÍ¿¼Á¿µÄÒªµã¡£¡£¡£¡£¡£09ÔÂ03ÈÕÍí19:00--20:00£¬ £¬£¬£¬£¬£¬ÕµǼª²©Ê¿´øÎÒÃÇÒ»Æð×ß½øË«¿¹ÒÔ¼°Ë«¿¹µÄÉúÎïÆÊÎö¡£¡£¡£¡£¡£

¡¾ÔÆ¿ÎÌá¿¶àëÄÀàÒ©ÎïÉúÎïÆÊÎöµÄÌôÕ½Óë¶Ô²ß
2020-03-06
2020Äê3ÔÂ6ÈÕÏÂÖ磬 £¬£¬£¬£¬£¬ÃÀ¸ß÷ÉúÎï¼¼ÊõÒ©ÎïÆÊÎö²¿Ö÷ÈÎÕµǼª×öÁË¡°¶àëÄÀàÒ©ÎïÉúÎïÆÊÎöµÄÌôÕ½Óë¶Ô²ß¡±×¨Ìⱨ¸æ£¬ £¬£¬£¬£¬£¬»¶Ó­Ô¢Ä¿»Ø·ÅÊÓÆµ¡£¡£¡£¡£¡£
ÖÜȫ֧³ÖÒßÃçÑз¢£¡ÃÀ¸ß÷mRNAÒßÃçÉúÎïÆÊÎö¼¼Êõƽ̨
2020-12-12
ÃÀ¸ß÷ÉúÎïÒ½Ò©ºã¾ÃΪÖÖÖÖÐÂÐÍÉúÎï¼¼ÊõÒ©¼°ÒßÃçµÄÇå¾²ÐÔºÍÓÐÓÃÐÔÆÀ¼ÛÌṩȫ·½Î»Ö§³Ö£¬ £¬£¬£¬£¬£¬¹«Ë¾ÏàÖú£¬ £¬£¬£¬£¬£¬ÖÂÁ¦ÓÚLNP-mRNAÀàÒ©ÎïºÍÒßÃçµÄÓÐÓÃÐÔ¼°Çå¾²ÐÔÆÀ¼ÛÆÊÎöÊÂÇ飬 £¬£¬£¬£¬£¬»ýÀÛÁ˸»ºñµÄÂÄÀú£¬ £¬£¬£¬£¬£¬½¨É轡ȫÁËÐÂÐÍmRNAÒßÃçµÄÏà¹ØÉúÎïÆÊÎö¼¼Êõƽ̨¡£¡£¡£¡£¡£
¡Á
ËÑË÷ÑéÖ¤
µã»÷Çл»
¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿